New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
15:37 EDTGILDGilead falls after recalling select lots of HIV drug
Gilead Sciences (GILD) is down about 4% in afternoon trade after the firm initiated a recall of select lots of its Atripla treatment. WHAT'S NEW: According to a post on the FDA's website, Gilead initiated a nationwide recall of of about 39,000 bottles of its Atripla treatment. Atripla is a treatment for HIV-1 infection in adults and children at least 12 years old. The recall relates to the presence of red silicone rubber particulates in the lot. ANALYST REACTION: In a note to investors following the recall, analysts at Deutsche Bank said Gilead management reiterated that the recall is a minor issue. Gilead said a typical quality check found small particles and the company proactively contacted the FDA to issue the voluntary recall of these lots. Gilead also said the recalled product comes from their 3rd party manufacturer in China that only makes this drug and noted it has multiple manufacturers for Atripla. The firm said it would be buyers on any weakness in Gilead shares following the news. Deutsche Bank maintains a Buy rating and $132 price target on shares. PRICE ACTION: In late afternoon trade, shares of Gilead are down $2.99 or 3.61%, to $79.88, though this is off the worst levels of the session.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB BAC DIS NFLX X YNDX GILD PANW SUNW
November 23, 2015
09:39 EDTGILDActive equity options trading on open
Subscribe for More Information
06:41 EDTGILDGilead granted marketing authorization in EU for Genvoya
Subscribe for More Information
November 18, 2015
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
November 17, 2015
10:47 EDTGILDBristol-Myers strength attributed to sale chatter
The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.
November 16, 2015
09:04 EDTGILDGilead says Phase 3 Zydelig study shows 'clinical benefit'
Gilead announced that its Phase 3 Study 115 evaluating Zydelig added to standard therapy in previously-treated chronic lymphocytic leukemia patients will be unblinded early. The DMC recommendation is based upon a predefined interim analysis indicating a statistically significant benefit in efficacy for progression-free survival and overall survival in patients receiving Zydelig plus bendamustine and rituximab, compared to those receiving only bendamustine and rituximab. The safety profile of Zydelig was consistent with prior studies. Detailed results from this study will be presented during a late-breaking abstracts session at the Annual Meeting of the American Society of Hematology in Orlando, Florida taking place December 5-8. "The clinical benefit observed in this Phase 3 study adds to the body of evidence demonstrating the potential of Zydelig-containing treatment regimens for patients with previously treated CLL," said Norbert W. Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. "We look forward to sharing the detailed scientific data with the hematology community at the upcoming ASH meeting."
November 15, 2015
20:17 EDTGILDGilead presents results from four Phase 3 studies of sofosbuvir/velpatasvir
Subscribe for More Information
15:47 EDTGILDGilead reports data from multiple studies of Viread, TAF, others
Subscribe for More Information
November 12, 2015
17:55 EDTGILDGilead announces FDA approval of Harvoni
Gilead Sciences announced that the U.S. FDA has approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection and in patients co-infected with HIV. In addition, Harvoni plus ribavirin for 12 weeks was approved as an alternate therapy to 24 weeks of Harvoni for treatment-experienced, genotype 1 patients with cirrhosis. Harvoni received regulatory approval for the treatment of chronic HCV genotype 1 infection in adults in the United States in October 2014.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use